Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL635664 | 1.00 | ESR1 (0.38) | ESR1ESR2LMNAGRIN1GRIN2A | |
| SCHEMBL4096134 | 1.00 | ESR1 (0.38) | ESR1ESR2LMNAGRIN1GRIN2A | |
| Ammonia Solution, Strong SCHEMBL8948373 | 0.97 | ESR1 (0.37) | ESR1ESR2LMNAGRIN1GRIN2A | |
| SCHEMBL635941 | 0.85 | ESR1 (0.35) | ESR1ESR2 | |
| SCHEMBL5586346 | 0.80 | — | — | |
| SCHEMBL4413629 | 0.80 | ESR1 (0.45) | ESR1ESR2CYP2D6 | |
| SCHEMBL540773 | 0.79 | ESR1 (0.38) | ESR1ESR2LMNAGRIN1GRIN2A | |
| SCHEMBL24927799 | 0.75 | — | — | |
| SCHEMBL1003423 | 0.74 | LMNA (0.31) | ESR1LMNAGRIN1GRIN2ASLC22A1 | |
| SCHEMBL910279 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108779245-A | Polyamide resin and film formed therefrom | 宇部兴产株式会社 | 2018-11-09 | — | — | CN | claimed |
| CN-108475554-A | Automation field device and method for the production thereof | 恩德斯+豪斯流量技术股份有限公司 | 2018-08-31 | — | — | CN | claimed |
| CN-106605014-A | Bio-derived polyurethane fiber | 英威达技术有限公司 | 2017-04-26 | — | — | CN | claimed |
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | claimed |
| WO-2014082910-A1 | METHOD FOR PRODUCING POLYISOCYANATES | BASF SE (DE) | 2014-06-05 | — | — | WO | claimed |
| WO-2012163894-A2 | PROCESS FOR PREPARING POLYISOCYANATES | BASF SE (DE) | 2012-12-06 | — | — | WO | claimed |
| US-20110033422-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | SCHERING CORPORATION | 2011-02-10 | — | — | US | claimed |
| EP-2260839-A2 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | Merz Pharma GmbH & Co. KGaA (DE) | 2010-12-15 | — | — | EP | claimed |
| US-7816339-B2 | Treatments for Flaviviridae virus infection | SCHERING CORPORATION (US) | 2010-10-19 | — | — | US | claimed |
| US-20090209483-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | SCHERING CORPORATION | 2009-08-20 | — | — | US | claimed |
| WO-2005079779-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-01 | — | — | WO | claimed |
| EP-1556019-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | Merz Pharma GmbH & Co. KGaA (DE) | 2005-07-27 | — | — | EP | claimed |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | FOREST LABORATORIES, INC. (US) | 2005-05-26 | — | — | US | claimed |
| EP-1523309-A2 | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN TAU | Iqbal, Khalid (US) | 2005-04-20 | — | — | EP | claimed |
| WO-2005009421-A2 | THE USE OF 1-AMINO-ALKYLCYCLOHEXANE COMPOUNDS IN THE TREATMENT OF PAIN HYPERSENSITIVITY | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-02-03 | — | — | WO | claimed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | claimed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | claimed |
| WO-2004009062-A2 | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau | IQBAL KHALID (US) | 2004-01-29 | — | — | WO | claimed |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2004-01-29 | — | — | US | claimed |
| US-6034134-A | 1-Amino-alkylcyclohexane NMDA receptor antagonists | MERZ + CO. GMBH & CO. (DE) | 2000-03-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033422-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, EIF2AK2, HNRNPC | ESR1 4393/4885ESR2 3148/4885LMNA 2114/4885 |
| US-20090209483-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, EIF2AK2, HNRNPC | ESR1 4393/4885ESR2 3148/4885LMNA 2114/4885 |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN2A, GRIN1, MAPT | ESR1 3770/4885ESR2 2650/4885LMNA 3937/4885 |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | APP, BACE1, PSEN1 | ESR1 3538/4885ESR2 2335/4885LMNA 837/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | ESR1 719/4885ESR2 677/4885LMNA 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.